Thromb Haemost 2021; 121(07): 976-978
DOI: 10.1055/a-1326-7028
T&H Images

Coronary Plaque Erosion after Abemaciclib Treatment Onset: An Unknown Side Effect?

Alberto Vera
1  Instituto de Investigación Sanitaria (IIS-IP), Hospital Universitario de la Princesa, CIBERCV, Madrid, Spain
,
Fernando Rivero
1  Instituto de Investigación Sanitaria (IIS-IP), Hospital Universitario de la Princesa, CIBERCV, Madrid, Spain
,
Jorge Salamanca
1  Instituto de Investigación Sanitaria (IIS-IP), Hospital Universitario de la Princesa, CIBERCV, Madrid, Spain
,
Teresa Alvarado-Casas
1  Instituto de Investigación Sanitaria (IIS-IP), Hospital Universitario de la Princesa, CIBERCV, Madrid, Spain
,
Fernando Alfonso
1  Instituto de Investigación Sanitaria (IIS-IP), Hospital Universitario de la Princesa, CIBERCV, Madrid, Spain
› Author Affiliations

Abstract

The current article describes a 72-year-old woman who suffered an acute myocardial infarction due to plaque erosion (PE) 2 weeks after abemaciclib treatment onset due to advanced breast cancer. Abemaciclib is a cyclin-dependent kinase 4 and 6 inhibitor that has recently demonstrated efficacy and safety in advanced breast cancer. Of major concern, however, reported thromboembolic rates in randomized clinical trials testing this drug range from 0.6 to 5%. To the best of our knowledge this is the first thrombotic coronary side effect ever reported. We suggest that a treatment that increases thromboembolic risk, such abemaciclib, may have triggered PE in our patient, 15 days after abemaciclib initiation. New molecules are promising in cancer treatment; however, care must be paid to their potential cardiotoxic effects.



Publication History

Received: 07 November 2020

Accepted: 27 November 2020

Publication Date:
01 December 2020 (online)

© 2020. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany